VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2020 | ALTERNATE: fulvestrant and/or anastrozole in ER+ HER2- postmenopausal breast cancer

Cynthia X. Ma, MD, PhD, Washington University School of Medicine, St. Louis, MI, outlines the ALTERNATE trial (NCT01953588), investigating neoadjuvant endocrine therapy with fulvestrant or the combination of anastrozole and fulvestrant for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer in postmenopausal women. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter